Skip to main content

Table 1 Comparison between WHO, RECIST, and RECIST 1.1 Criteria

From: Imaging biomarkers for evaluating tumor response: RECIST and beyond

  WHO RECIST RECIST 1.1
Lesion measurement
 Imaging modalities N/A Chest X-ray, CT, and MRI Chest X-ray, CT, MRI, and 18 F-FDG PET
 Limitation of measurable lesions N/A • 10 mm on spiral CT
• 20 mm on non-spiral CT or MRI
• Chest X-ray: if clearly defined
• Clinical: 20 mm
• 10 mm on CT/MRI (slice thickness ≤ 5 mm), or 2 x slice thickness (if thickness > 5 mm )
• Chest X-ray: 20 mm
• Clinical: 10 mm (must be measurable with calipers)
•18 F-FDG PET: included only in the detection of new lesions
 Lymph node Unspecified Unspecified CT: short axis
• ≥ 15 mm is measurable, target lesion
• 10–14 mm is non-measurable, non-target lesion
• < 10 mm is normal
 Method of measurement Cross-product of the longest diameter and the longest perpendicular diameter Longest diameter in the axial plane Longest diameter in the axial plane
 Numbers of lesions measured N/A up to 10 lesions (≤ 5 in any one organ) up to 5 lesions (≤ 2 in any one organ)
Response evaluation
 Complete Response (CR) Disappearance of all lesions Disappearance of all lesions Disappearance of all lesions and pathologic lymph nodes
 Partial Response (PR) ≥ 50 % decrease in the sum of the area ≥ 30 % decrease in the sum of the longest diameter ≥ 30 % decrease in the sum of the longest diameter
 Stable Disease (SD) Neither PR nor PD Neither PR nor PD Neither PR nor PD
 Progressive Disease (PD) ≥ 25 % increase in the sum of the area ≥ 20 % increase in the sum of longest diameters, or new lesions ≥ 20 % increase in the sum of longest diameters with an absolute increase of ≥ 5 mm, or new lesions
  1. CT computed tomography, MRI magnetic resonance imaging, N/A not applicable, PET positron emission tomography, RECIST Response Evaluation Criteria in Solid Tumor, WHO World Health Organization